Revenue Recognition

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Revenue Recognition

18. Revenue Recognition

The following table provides information about disaggregated revenue by product and services:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Product sales, net	$	894	$	3,393	$	12,291	$	26,199
Processing and storage fees, net		1,448		1,292		4,131		3,857
License, royalty and other		2,942		4,611		6,024		6,032
Net revenues	$	5,284	$	9,296	$	22,446	$	36,088

Net revenues include: (i) sales of biomaterial products, including Biovance, Biovance 3L, Rebound^TM, Interfyl, and CentaFlex, of which our direct sales are included in Product Sales while sales through our network of distribution partners are included in License, royalty and other; and (ii) the collection, processing and storage of umbilical cord and placental blood and tissue after full-term pregnancies, collectively, Services.

The following table provides changes in deferred revenue from contract liabilities:

	2025
Balance at January 1	$	6,255
Deferral of revenue*		6,678
Recognition of unearned revenue		(4,585	)
Balance at September 30	$	8,348

(1)	Deferral of revenue includes $1,309 in 2025 resulting from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.
(2)	Deferral of revenue includes $2,890 in 2025 resulting from product purchase credits issued to Defeye as consideration for Defeye’s Series Seed – 2 Preferred Stock (Note 9 – Investments – Equity Securities).
(3)	Recognition of unearned revenue includes $3,276 that was included in the beginning deferred revenue balance at January 1, 2025.